Table 3.
SCIg dosing of the vial and PFS cohorts overall, and stratified by SCIg administration method (pump and manual push).
| Dosing | Vial cohort (A) | PFS cohort (B) | p values | ||
|---|---|---|---|---|---|
| Summary | n | Summary | n | A vs. B | |
| All respondents | |||||
| SCIg dose (g/week) (median [IQR]) | 12 [9, 16] | 63 | 10 [8, 12] | 110 | 0.02 |
| SCIg dose per bodyweight (g/week/kg) (median [IQR]) | 0.15 [0.11, 0.19] | 56 | 0.13 [0.10, 0.17] | 100 | 0.06 |
| Pump subgroup | |||||
| SCIg dose (g/week) (median [IQR]) | 12 [10, 14] | 37 | 10 [8, 16] | 37 | 0.30 |
| SCIg dose per bodyweight (g/week/kg) (median [IQR]) | 0.15 [0.12, 0.19] | 32 | 0.15 [0.11, 0.20] | 34 | 0.66 |
| Manual push subgroup | |||||
| SCIg dose (g/week) (median [IQR]) | 10 [8, 16] | 26 | 10 [8, 12] | 73 | 0.18 |
| SCIg dose per bodyweight (g/week/kg) (median [IQR]) | 0.14 [0.11, 0.30] | 24 | 0.12 [0.10, 0.16] | 66 | 0.14 |
Data were compared using the Mann-Whitney test due to the non-normality (skewness) of the distributions. Significant p-values are highlighted in bold. g grams, IQR interquartile range, kg kilogram, PFS pre-filled syringes, SCIg subcutaneous immunoglobulin